Difference between revisions of "Epithelioid sarcoma"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "Biomarker eligiblity criteria" to "Biomarker eligibility criteria") |
m |
||
Line 13: | Line 13: | ||
=All lines of therapy= | =All lines of therapy= | ||
==Tazemetostat monotherapy {{#subobject:a9367b|Regimen=1}}== | ==Tazemetostat monotherapy {{#subobject:a9367b|Regimen=1}}== | ||
− | + | <div class="toccolours" style="background-color:#eeeeee"> | |
===Regimen {{#subobject:43c238|Variant=1}}=== | ===Regimen {{#subobject:43c238|Variant=1}}=== | ||
{| class="wikitable" style="color:white; background-color:#404040" | {| class="wikitable" style="color:white; background-color:#404040" | ||
Line 25: | Line 25: | ||
|- | |- | ||
|[https://doi.org/10.1016/s1470-2045(20)30451-4 Gounder et al. 2020 (EZH-202)] | |[https://doi.org/10.1016/s1470-2045(20)30451-4 Gounder et al. 2020 (EZH-202)] | ||
+ | {| class="wikitable" style="margin:auto; color:white; background-color:#1B4F26" | ||
+ | |'''[https://www.esmo.org/guidelines/esmo-mcbs/esmo-mcbs-scorecards/scorecard-252-1 <span style="color:white;">ESMO-MCBS (1)</span>]''' | ||
+ | |- | ||
+ | |} | ||
|2015-2017 | |2015-2017 | ||
| style="background-color:#91cf61" |Phase 2 (RT) | | style="background-color:#91cf61" |Phase 2 (RT) | ||
|- | |- | ||
|} | |} | ||
+ | <div class="toccolours" style="background-color:#fdcdac"> | ||
====Biomarker eligibility criteria==== | ====Biomarker eligibility criteria==== | ||
One or both of the following: | One or both of the following: | ||
*Loss of INI1 expression by IHC | *Loss of INI1 expression by IHC | ||
*Biallelic SMARCB1 alterations | *Biallelic SMARCB1 alterations | ||
+ | </div> | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Targeted therapy==== | ====Targeted therapy==== | ||
*[[Tazemetostat (Tazverik)]] 800 mg PO twice per day | *[[Tazemetostat (Tazverik)]] 800 mg PO twice per day | ||
'''28-day cycles''' | '''28-day cycles''' | ||
− | + | </div></div> | |
===References=== | ===References=== | ||
<!-- # '''Abstract:''' Mrinal M. Gounder, Silvia Stacchiotti, Patrick Schöffski, Steven Attia, Antoine Italiano, Robin Jones, George D. Demetri, Stephen Blakemore, Alicia Clawson, Scott Daigle, Scott Ribich, Maria Roche, Jill Rodstrom, Peter T.C. Ho, and Gregory Michael Cote. Phase 2 multicenter study of the EZH2 inhibitor tazemetostat in adults with INI1 negative epithelioid sarcoma (NCT02601950). Journal of Clinical Oncology 2017 35:15_suppl, 11058-11058. [https://doi.org/10.1200/JCO.2017.35.15_suppl.11058 link to abstract] [https://clinicaltrials.gov/ct2/show/NCT02601950 CT.gov] --> | <!-- # '''Abstract:''' Mrinal M. Gounder, Silvia Stacchiotti, Patrick Schöffski, Steven Attia, Antoine Italiano, Robin Jones, George D. Demetri, Stephen Blakemore, Alicia Clawson, Scott Daigle, Scott Ribich, Maria Roche, Jill Rodstrom, Peter T.C. Ho, and Gregory Michael Cote. Phase 2 multicenter study of the EZH2 inhibitor tazemetostat in adults with INI1 negative epithelioid sarcoma (NCT02601950). Journal of Clinical Oncology 2017 35:15_suppl, 11058-11058. [https://doi.org/10.1200/JCO.2017.35.15_suppl.11058 link to abstract] [https://clinicaltrials.gov/ct2/show/NCT02601950 CT.gov] --> |
Revision as of 13:55, 26 February 2023
Section editor transclusions Note: these are regimens tested in subtype-specific populations, please see the main soft tissue sarcoma page for other regimens.
1 regimens on this page
1 variants on this page
|
All lines of therapy
Tazemetostat monotherapy
Regimen
FDA-recommended dose |
Study | Years of enrollment | Evidence | |
---|---|---|---|
Gounder et al. 2020 (EZH-202)
|
2015-2017 | Phase 2 (RT) |
Biomarker eligibility criteria
One or both of the following:
- Loss of INI1 expression by IHC
- Biallelic SMARCB1 alterations
References
- EZH-202: Gounder M, Schöffski P, Jones RL, Agulnik M, Cote GM, Villalobos VM, Attia S, Chugh R, Chen TW, Jahan T, Loggers ET, Gupta A, Italiano A, Demetri GD, Ratan R, Davis LE, Mir O, Dileo P, Van Tine BA, Pressey JG, Lingaraj T, Rajarethinam A, Sierra L, Agarwal S, Stacchiotti S. Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study. Lancet Oncol. 2020 Nov;21(11):1423-1432. Epub 2020 Oct 6. link to original article contains dosing details in abstract PubMed NCT02601950